Media

What's makes SynDevRx different?  Our drug development plan takes a distinct productization approach.  For patients to benefit from Dr. Folkman's exceptional science and technology, it must not only exceed current standards of care but also be cost effective. 

We believe our lead compound - Caplostatin™- is the next generation of anti-angiogenic therapies. It is the combination of a broad-spectrum active moiety with a unique biological target conjugated to a tumor-targeting nano-particle. This combination has shown activity without the toxicities of other leading anti-angiogenic drugs currently on the market and under development.

The company furnishes the media with current information on our clinical progress in a timely way.  This section is reserved for our regular updates

For more information, please contact:

Jim Shanahan

VP Business Development
617.401.3110 (office)

jshanahan@syndevrx.com